
Smart Cells Programmed to Reverse Brain Aging | Dr. Julie Andersen
In this interview, Dr. Julie Andersen from the Buck Institute for Research on Aging explains how mitophagy (the cell's mitochondrial recycling system) and cellular senescence affect brain health during aging. She describes groundbreaking research approaches that could halt neurodegeneration long before symptoms appear.
Key PointsThe Role of Mitochondria in the Brain
- The brain makes up only about 2% of body mass but consumes 20% of resting energy – mainly produced by mitochondria.
- Neurons are postmitotic and cannot divide; they must maintain their mitochondria for decades.
- Mitophagy is the cell's recycling system: damaged mitochondria are broken down in lysosomes, and their building blocks are reused to create new, healthy mitochondria.
- With age, mitophagy becomes less efficient, especially in diseases like Alzheimer's and Parkinson's.
Brain Immune Cells and Inflammation
- Microglia and astrocytes support neurons but can release pro-inflammatory factors under chronic stress ("inflammaging").
- Damaged mitochondria release mitochondrial DNA into the cytoplasm, activating the cGAS-STING pathway and triggering "sterile inflammation."
- Causality is not linear: mitochondrial damage, protein aggregation, and inflammation reinforce each other in a vicious cycle.
Senescence and Targeted Therapies
- Senescent astrocytes lose their protective function and secrete inflammatory factors (SASP).
- A classic senolytic at too high a dose can also kill healthy neurons – a major challenge for targeted treatment.
- A novel approach uses genetically engineered regulatory T cells that cross the blood-brain barrier and specifically recognize pathologies such as A-beta, eliminating them locally.
Urolithin A – "Calm, Don't Kill"
- Urolithin A is a gut metabolite derived from ellagitannins (pomegranates, berries, nuts) and can boost mitophagy.
- In senescent cells, it acts as a senomorphic agent: it reduces the inflammatory SASP phenotype without killing the cells.
- Research shows it decreases mitochondrial DNA release into the cytosol and dampens STING activation – but only in senescent cells, not healthy ones.
Biomarkers and Outlook
- There are still no reliable, clinically usable biomarkers for brain senescence.
- Promising candidates are neuron-derived extracellular vesicles in plasma, which may contain fragments of mitochondrial DNA or synaptic proteins.
- Dr. Andersen sees the combination of mitophagy inducers, senolytics/senomorphics, and precise biomarker development as the most important path to protecting the aging brain.






